Optimizing Synthetic miRNA Minigene Architecture for Efficient miRNA Hairpin Concatenation and Multi-target Gene Knockdown.
CCR5
NOX3
cochlea
hematopoietic stem cells
lentivector transduction
miRNA
miRNA hairpins concatenation
multi-target gene knockdown
siRNA
synthetic miRNA minigene
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
01 Mar 2019
01 Mar 2019
Historique:
received:
06
06
2017
revised:
30
11
2018
accepted:
01
12
2018
pubmed:
22
1
2019
medline:
22
1
2019
entrez:
22
1
2019
Statut:
ppublish
Résumé
Synthetic microRNA (miRNA) minigenes (SMIGs) have a major potential for molecular therapy; however, their optimal architecture still needs to be determined. We have previously optimized the stem structure of miRNA hairpins for efficient gene knockdown. Here, we investigate the overall architecture of SMIGs driven by polymerase II-dependent promoters. When miRNA hairpins were placed directly behind the promoter, gene knockdown was inefficient as compared with constructs containing an intercalated sequence ("spacer"). Spacer sequence was relevant for knockdown efficiency and concatenation potential: GFP-based sequences (even when truncated or including stop codons) were particularly efficient. In contrast, a spacer of similar length based on a CD4 intronic sequence was entirely inefficient. Spacer sequences influenced miRNA steady-state levels without affecting transcript stability. We demonstrate that with an optimized spacer, up to five concatenated hairpins targeting two different genes are efficiently expressed and able to knock down their respective targets. Transplantation of hematopoietic stem cells containing a CCR5 knockdown SMIG demonstrated a sustained in vivo efficacy of our approach. In summary, we have defined features that optimize SMIG efficiency. Based on these results, optimized knockdown of genes of interest, such as the HIV co-receptor CCR5 and the NADPH oxidase subunit p22
Identifiants
pubmed: 30665184
pii: S2162-2531(18)30319-6
doi: 10.1016/j.omtn.2018.12.004
pmc: PMC6350225
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
351-363Informations de copyright
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Blood. 2000 Nov 15;96(10):3392-8
pubmed: 11071633
Oncogene. 2001 Jan 25;20(4):440-50
pubmed: 11313975
Gene Ther. 2003 May;10(9):818-21
pubmed: 12704422
Cell. 2003 Oct 17;115(2):199-208
pubmed: 14567917
Int J Clin Lab Res. 1992;22(3):159-64
pubmed: 1520913
EMBO J. 2004 Oct 13;23(20):4051-60
pubmed: 15372072
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13212-7
pubmed: 16141338
Cell. 2006 Jun 2;125(5):887-901
pubmed: 16751099
Biotechniques. 2006 Jul;41(1):59-63
pubmed: 16869514
J Virol. 2007 Mar;81(6):2861-8
pubmed: 17192312
Nature. 2007 Jul 5;448(7149):83-6
pubmed: 17589500
Nucleic Acids Res. 2008 May;36(9):2811-24
pubmed: 18346971
RNA. 2008 Sep;14(9):1834-44
pubmed: 18697922
Mol Ther. 2009 Jan;17(1):169-75
pubmed: 19002161
Mol Cell Biol. 1991 May;11(5):2832-41
pubmed: 1901950
Nat Cell Biol. 2009 Mar;11(3):228-34
pubmed: 19255566
Mol Biotechnol. 2010 Sep;46(1):34-40
pubmed: 20300885
Br J Pharmacol. 2011 Sep;164(2b):507-20
pubmed: 21501142
Methods Mol Biol. 2011;737:183-209
pubmed: 21590398
Hum Gene Ther. 2011 Oct;22(10):1255-67
pubmed: 21761975
Silence. 2011 Oct 26;2:8
pubmed: 22029761
Nucleic Acids Res. 2012 Oct;40(19):9863-75
pubmed: 22848108
Methods Mol Biol. 2013;942:233-57
pubmed: 23027055
Mol Ther. 2013 Jan;21(1):217-27
pubmed: 23089734
Front Biosci (Landmark Ed). 2013 Jan 01;18:58-79
pubmed: 23276909
Mol Ther. 2013 Mar;21(3):588-601
pubmed: 23295950
Science. 2013 Aug 23;341(6148):1233151
pubmed: 23845947
Science. 2013 Aug 23;341(6148):1233158
pubmed: 23845948
J Biotechnol. 2014 Jan;169:71-81
pubmed: 24252659
Mol Ther Nucleic Acids. 2014 Oct 28;3:e207
pubmed: 25350582
Transcription. 2014;5(1):e27639
pubmed: 25764110
Cell. 2015 Jul 2;162(1):96-107
pubmed: 26140593
PLoS One. 2015 Aug 18;10(8):e0135919
pubmed: 26285215
Curr Pharm Des. 2015;21(41):5977-87
pubmed: 26510434
Nucleic Acids Res. 2016 Mar 18;44(5):e48
pubmed: 26582923
Mol Biosyst. 2016 Jan;12(1):295-312
pubmed: 26617199
J Virol Methods. 2016 Sep;235:26-33
pubmed: 27181212
Science. 2016 Jun 17;352(6292):1417-20
pubmed: 27313039
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143
pubmed: 28918016